---
layout: post
title: "Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients With Type 2 Diabetes Mellitus; Guidance for Industry and Food and Drug Administration Staff; Availability"
date: 2026-02-05 18:59:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-09738
original_published: 2022-05-06 00:00:00 +0000
significance: 8.00
---

# Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients With Type 2 Diabetes Mellitus; Guidance for Industry and Food and Drug Administration Staff; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 06, 2022 00:00 UTC
**Document Number:** 2022-09738

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus." This guidance provides recommendations for feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with Type 2 Diabetes Mellitus. These medical devices are intended to therapeutically reduce glycated hemoglobin in Type 2 Diabetes Mellitus patients independent of medication (e.g., insulin) delivery.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/06/2022-09738/feasibility-and-early-feasibility-clinical-studies-for-certain-medical-devices-intended-to)
- API: https://www.federalregister.gov/api/v1/documents/2022-09738

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
